Literature DB >> 19179466

Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Celine M Vachon1, Robert A Kyle, Terry M Therneau, Barbara J Foreman, Dirk R Larson, Colin L Colby, Tara K Phelps, Angela Dispenzieri, Shaji K Kumar, Jerry A Katzmann, S Vincent Rajkumar.   

Abstract

We examined whether monoclonal gammopathy of undetermined significance (MGUS) is increased in first-degree relatives of multiple myeloma (MM) or MGUS patients. Probands were recruited from a population-based prevalence study (MGUS) and the Mayo Clinic (MM). Serum samples were collected from first-degree relatives older than 40 years and subjected to electrophoresis and immunofixation. The prevalence of MGUS in relatives was compared with population-based rates. Nine-hundred eleven relatives of 232 MM and 97 MGUS probands were studied. By electrophoresis, MGUS was detected in 55 (6%) relatives, and immunofixation identified 28 additional relatives for an age- and sex-adjusted prevalence of 8.1% (95% CI, 6.3 to 9.8). The prevalence of MGUS in relatives increased with age (1.9%, 6.9%, 11.6%, 14.6%, 21.0% for ages 40-49, 50-59, 60-69, 70-79, >/= 80 years, respectively; P < .001). Using similar MGUS detection methods, there was a higher risk of MGUS in relatives (age-adjusted risk ratio [RR], 2.6; 95% CI, 1.9 to 3.4) compared with the reference population. The increased risk was seen among relatives of MM (RR, 2.0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179466      PMCID: PMC2716020          DOI: 10.1182/blood-2008-12-192575

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Familial multiple myeloma. II. Final pathological findings in two brothers and a sister.

Authors:  L L Alexander; D L Benninghoff
Journal:  J Natl Med Assoc       Date:  1967-07       Impact factor: 1.798

2.  Familial multiple myeloma.

Authors:  L L Alexander; D L Benninghoff
Journal:  J Natl Med Assoc       Date:  1965-11       Impact factor: 1.798

3.  Familial multiple myeloma: report of fifteen families.

Authors:  B Grosbois; P Jego; M Attal; C Payen; M J Rapp; J G Fuzibet; M Maigre; R Bataille
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

4.  Multiple myeloma and family history of cancer among blacks and whites in the U.S.

Authors:  L M Brown; M S Linet; R S Greenberg; D T Silverman; R B Hayes; G M Swanson; A G Schwartz; J B Schoenberg; L M Pottern; J F Fraumeni
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

5.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.

Authors:  H J Cohen; J Crawford; M K Rao; C F Pieper; M S Currie
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

8.  Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study.

Authors:  M Eriksson; B Hållberg
Journal:  Cancer Causes Control       Date:  1992-01       Impact factor: 2.506

9.  Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival.

Authors:  L J Melton; T M Therneau; D R Larson
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

10.  Multiple myeloma and family history of cancer. A case-control study.

Authors:  C C Bourguet; S Grufferman; E Delzell; E R DeLong; H J Cohen
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

View more
  57 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 2.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

3.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

Review 4.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

Review 5.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

Review 6.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 7.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

Review 8.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

Review 10.  Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Vincent S Rajkumar
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.